Executive field guide · Responsible AI operations
Build an AI control tower—not a collection of disconnected pilots
Healthcare organizations do not create durable value by acquiring the most models. They create it by choosing consequential problems, fitting technology into real work, protecting patients and staff, and learning from performance after deployment.
Artificial intelligence has moved from an innovation-lab topic to an operating-model decision. Predictive tools influence clinical decisions and capacity planning. Computer vision supports imaging and logistics. Natural-language systems summarize records, draft communications, and reduce documentation burden. Generative AI can accelerate knowledge work across service lines. Yet the central executive question is no longer, “Where can we use AI?” It is, “Where should we use it, under what controls, and how will we know it is helping?”
That distinction matters. A model can perform well in a retrospective test and still fail in practice because the inputs differ, the alert reaches the wrong person, the workflow adds clicks, the output is misunderstood, or the organization never defined who owns the result. A tool can save minutes for one employee while shifting review work, risk, or anxiety to another. A vendor can describe impressive accuracy without showing whether performance holds for the populations, settings, devices, and staffing patterns in a particular health system.
Healthcare executives therefore need an enterprise discipline that connects strategy, clinical governance, operations, technology, security, compliance, workforce experience, and finance. Think of that discipline as an AI control tower: one coordinated view of every use case, its risk tier, accountable owner, evidence, workflow, performance, and disposition. The control tower does not centralize every decision. It creates common rules, usable information, and escalation paths so teams can move faster without becoming careless.
Start with decisions, not demonstrations
Technology demonstrations are seductive because they compress complexity into a few polished minutes. Real healthcare work is different. It includes incomplete data, interruptions, handoffs, exceptions, conflicting goals, and people operating under time pressure. The most reliable way to select AI investments is to begin with a decision or task that already has a named owner and an observable burden.
Describe the current state before discussing products. Who performs the work? What information do they need? How long does it take? Where do errors, delays, rework, denials, or inequities occur? What happens when the answer is uncertain? This baseline prevents “solutionism,” in which an attractive capability is attached to a problem that does not warrant it. It also gives the organization a fair comparison between an AI-enabled redesign and lower-cost alternatives such as standardization, staffing changes, rules-based automation, training, or removal of unnecessary steps.
Prioritize use cases through four filters: strategic relevance, achievable benefit, implementation readiness, and potential harm. A low-risk administrative task with clean data and a clear time burden may be a better first investment than a clinically dramatic use case with uncertain accountability. Conversely, a high-impact clinical opportunity may warrant deliberate investment when the disease burden is material, the evidence is credible, clinicians are engaged, and safeguards can be tested.
| Use-case zone | Promising starting points | Primary executive caution |
|---|---|---|
| Administrative | Document classification, prior-authorization preparation, scheduling support, coding assistance, contact-center routing | Automation can create hidden review queues or reproduce outdated policies. |
| Operational | Capacity forecasting, staffing scenarios, supply planning, length-of-stay barriers, preventive maintenance | Forecasts become unreliable when local processes or demand patterns change. |
| Clinical support | Imaging assistance, deterioration detection, medication safety, diagnostic support, care-gap identification | False reassurance, alert fatigue, subgroup performance, and unclear clinical responsibility. |
| Patient-facing | Navigation, education, translation support, symptom intake, reminders, portal assistance | Accessibility, health literacy, escalation failures, privacy, and overreliance on generated advice. |
Control layer 01
Create governance that helps teams make decisions
Governance should be a working operating system, not a ceremonial committee. It must distinguish between experimentation and production; define which use cases require clinical, privacy, security, legal, compliance, or patient review; and create a proportionate path from intake to retirement. The objective is not to make every project slow. It is to concentrate scrutiny where a failure could cause the greatest harm.
Establish an enterprise AI council sponsored by an executive with authority across clinical and administrative domains. Its permanent core should include clinical leadership, nursing, operations, information technology, data science, cybersecurity, privacy, compliance, legal counsel, quality and safety, human factors, workforce leadership, finance, and procurement. Add patient, caregiver, community, and frontline voices when the use case affects them. A small decision team can meet frequently, while subject-matter reviewers join based on risk.
Give the council a single inventory. Every internally developed, embedded, vendor-supplied, and employee-accessed AI capability belongs in it—including features quietly introduced through software updates. Record the intended use, prohibited uses, data inputs, output, vendor, version, deployment sites, user groups, risk tier, evidence, approvals, contract terms, monitoring plan, incident history, and accountable business and technical owners. Shadow AI cannot be managed if leaders do not know it exists.
Accountable owner
A named operational or clinical leader owns the outcome and workflow. The data-science team may own model engineering, but it should not own the care or business decision the model influences.
Bounded purpose
The approved use is explicit. “Assist emergency nurses with early identification of deterioration” is governable; “improve care with AI” is not. Document exclusions and conditions where users must not rely on the output.
Change authority
Define who may change thresholds, prompts, data feeds, interfaces, or models. Require impact assessment and regression testing when a material component changes.
Exit authority
Name who can pause the system, how users revert to a safe workflow, how events are investigated, and when leaders notify patients, regulators, payers, or partners.
The NIST AI Risk Management Framework offers a practical vocabulary: govern, map, measure, and manage. Its voluntary, use-case-agnostic structure is useful for health systems because it connects policies with contextual risk assessment, testing, and response. For generative systems, NIST’s Generative AI Profile extends that thinking to risks such as confabulation, privacy, information integrity, and human-AI interaction. An organization can map these principles to existing enterprise risk, quality, model-risk, change-control, and incident-response processes rather than creating a parallel bureaucracy.
Risk tiers should reflect impact, autonomy, exposure, and reversibility. A tool that reformats an internal meeting note is not equivalent to one that prioritizes patients, drafts a discharge plan, or recommends treatment. Higher tiers deserve stronger evidence, prospective validation, human-factors testing, formal approval, tighter access controls, more frequent monitoring, and a lower threshold for escalation. Reassess the tier when the use expands, the population changes, the model is updated, or staff begin using the output differently than intended.
Control layer 02
Demand evidence that travels from the lab to the local workflow
Evaluation is not a single accuracy number. It is a chain of evidence: technical performance, clinical or operational validity, usefulness in the intended workflow, equitable performance, safe human interaction, and sustained results after launch. Break that chain anywhere and a strong model can become a weak intervention.
Define the target and reference standard
State exactly what the system predicts, classifies, generates, or recommends; the time horizon; and the accepted standard used to judge it. Confirm that the target corresponds to an action the organization can take.
Reproduce vendor evidence
Review development data, exclusions, comparison groups, missing-data handling, external validation, confidence intervals, failure modes, and known limitations. Marketing summaries are not substitutes for technical documentation.
Validate with representative local data
Test the current version against the populations, sites, equipment, documentation patterns, and prevalence found locally. Report discrimination and calibration where relevant, not just an aggregate score.
Run in silent mode
Feed production data without exposing outputs to decision-makers. Confirm data integrity, latency, availability, case volume, subgroup performance, alert frequency, and the operational consequences of proposed thresholds.
Test people and workflow
Use realistic scenarios to observe comprehension, automation bias, alert fatigue, escalation, and recovery. Evaluate whether the interface communicates uncertainty and limitations at the moment of use.
Deploy progressively and monitor
Begin with a bounded site, team, or population; compare against a baseline or appropriate control; monitor balancing measures; and expand only when evidence supports it.
For predictive decision support integrated with certified health information technology, the federal direction emphasizes transparency and risk management. The Office of the National Coordinator’s Decision Support Interventions criterion addresses source attributes and risk analysis across validity, reliability, robustness, fairness, intelligibility, safety, security, and privacy. Even when a particular requirement applies directly to a certified health IT developer rather than a hospital, the categories form a valuable due-diligence checklist for buyers and governance teams.
Clinical AI that meets the definition of a medical device deserves another level of regulatory diligence. Confirm the exact product, version, intended use, and authorization rather than assuming a vendor’s entire platform is cleared. The FDA’s AI-enabled medical device list supports transparency about devices authorized for marketing in the United States. The FDA also emphasizes a total-product-life-cycle perspective, because performance can change as models, inputs, populations, clinical practice, and user behavior evolve.
A deployment decision is a clinical and operational hypothesis: if these users receive this output at this point in the workflow, then this action will change and this outcome will improve—without unacceptable harm elsewhere.
Measure more than model performance
Create a scorecard before go-live. Technical measures may include sensitivity, specificity, positive predictive value, calibration, error rates, completion rates, response latency, and uptime. Choose metrics based on the use case; a rare-event prediction can look impressive by accuracy while providing little practical value. Report uncertainty and the consequences of false positives and false negatives in terms leaders and frontline teams can understand.
Workflow measures show whether the output can be used: time to acknowledge, action rate, override rate, alert volume, queue age, handoffs, duplicate work, clicks, documentation time, escalation completion, and user-reported burden. Outcome measures connect the intervention to the mission: harm events, time to treatment, readmissions, avoidable days, denials, access, throughput, patient understanding, workforce retention, or cost per completed episode. Balancing measures detect what worsened, such as unnecessary testing, inequitable access, new review labor, alarm fatigue, or patient complaints.
Stratify meaningful measures by age, sex where clinically relevant, race and ethnicity, language, disability, payer, geography, site, and other locally important characteristics—while protecting privacy and avoiding unreliable conclusions from small samples. Fairness is not achieved by reporting equal aggregate performance. Leaders must examine whether the use case, data, thresholds, access channel, and resulting interventions distribute benefit and burden appropriately.
Control layer 03
Engineer data, privacy, and security as patient-safety foundations
AI performance inherits the quality and history of its data. Missing observations may represent gaps in access rather than absence of disease. A billing code may reflect reimbursement practice rather than clinical truth. A utilization-based label may encode unequal opportunity to receive care. Before development or procurement, a multidisciplinary team should trace each important data element from creation to use: who enters it, why it exists, when it becomes available, how it changes across sites, and what missingness means.
Data readiness includes identity matching, terminology, provenance, timeliness, completeness, representativeness, lineage, and change management. Interface teams need automated checks for schema changes, unit mismatches, impossible values, delayed feeds, duplicate records, and unexpected shifts. Owners need to know whether a model fails safely when an input is missing. Silent substitution of defaults may preserve uptime while degrading safety.
Privacy teams should establish the lawful and permitted basis for collection, use, disclosure, retention, and secondary use. Apply data minimization: if a task can be performed without protected or sensitive information, do not provide it. Separate development, testing, and production environments. Limit access by role, log activity, encrypt data in transit and at rest, and define retention and deletion requirements. Contracts should specify whether the vendor may use organizational data or prompts to train other models, where information is processed, which subprocessors are involved, how incidents are reported, and how data are returned or destroyed at termination.
Generative AI expands the threat surface. Prompts can leak sensitive information; retrieved documents can contain malicious instructions; outputs can expose data to unauthorized users; integrations can permit actions beyond the user’s role; and attackers can exploit model or supply-chain weaknesses. Treat an AI application as a complete system—not merely a model. Threat-model the user interface, identity layer, APIs, retrieval corpus, vector database, plugins, model provider, logging, monitoring, and downstream actions.
- Use approved enterprise tools with identity, role-based access, logging, and contractual protections; block or limit unsanctioned services where proportionate.
- Classify data and define which classes may enter each system, including explicit restrictions for protected health information and confidential business information.
- Test prompt injection, data exfiltration, unsafe tool use, excessive agency, insecure output handling, and denial-of-service scenarios.
- Require human confirmation before high-impact communications, orders, payments, record changes, or external actions.
- Maintain an incident pathway that connects cybersecurity, privacy, patient safety, quality, vendor management, and legal response.
- Prepare a downtime process and test whether staff can safely resume the underlying work when AI or its data feed is unavailable.
Procurement must secure ongoing visibility. Require vendors to disclose material model, prompt, data-source, hosting, and interface changes before deployment. Define service levels, audit rights, vulnerability response, performance reporting, notification windows, cooperation in investigation, and responsibilities for regulatory documentation. Avoid contract language that makes the health system solely responsible for evaluating a system the vendor can alter without notice. The goal is shared accountability supported by evidence.
Control layer 04
Design human oversight that changes what people actually do
“Human in the loop” is not a safeguard by itself. A hurried clinician clicking accept, a coder reviewing hundreds of suggestions, or a patient receiving an automated message may have little practical ability to detect an error. Effective oversight requires time, information, authority, competence, and an interface that makes uncertainty visible.
Define the human role for each use case. Is the system generating a draft, ranking options, flagging a case, recommending an action, or acting automatically? What must the user independently verify? What source information should appear beside the output? Which uncertainty or limitation should be visible? What requires escalation? When may a user override the system, and is a reason required? When is automation appropriate because the action is low impact and easily reversible?
Use human-factors testing with realistic users, not only project champions. Include night shifts, float staff, new employees, people using assistive technologies, and teams working under peak demand. Observe rather than simply ask. Users may say an interface is clear while missing a key limitation during a simulated case. Test how people behave when the system is correct repeatedly and then makes a subtle error; automation bias often appears after trust has accumulated.
Training should cover the use case, not a broad definition of AI. Staff need to understand the intended population, inputs, output, limitations, common failure modes, appropriate verification, escalation route, and downtime process. They should know that a confident tone does not equal accuracy and that generated text can fabricate details. Provide short, role-specific scenarios and refresh education after material changes.
Make feedback easy at the point of work. A user should be able to flag a questionable output, document the reason, and receive acknowledgment. Route clinical safety concerns differently from technical bugs or feature requests. Trend feedback and connect it with telemetry; repeated overrides may reveal a poor threshold, a population shift, a confusing interface, or a mismatch between policy and practice. Close the loop by telling teams what changed.
Communicate honestly with patients
Patients deserve understandable information when AI materially affects their interaction or care. The appropriate communication depends on the use: a low-risk administrative classifier is different from an automated conversation, a diagnostic aid, or a risk score that influences treatment. Explain the purpose, the role of the care team, meaningful limitations, how data are used, and how a patient can reach a person or request review. Avoid technical disclosures that satisfy a policy while obscuring practical meaning.
Accessibility and language quality must be validated, not assumed. Test patient-facing tools with people who have different levels of health literacy, preferred languages, cultural contexts, disabilities, and access to devices or broadband. Provide a reliable alternative channel. A digital tool that works well for connected English-speaking patients can widen disparities if leaders count only aggregate adoption.
Control layer 05
Treat generative AI as a system of bounded tasks
Generative AI can synthesize, draft, translate, summarize, and converse across unstructured information. Its flexibility creates value, but also makes the phrase “use a chatbot” dangerously vague. Decompose each application into a bounded task with a specific source set, user, output, review requirement, and prohibited action.
Consider ambient documentation. The intended benefit may be more attentive visits and less after-hours work. The system includes audio capture, consent or notification, speaker identification, transcription, summarization, templating, insertion into the record, clinician review, correction, signature, storage, and deletion. Evaluate each link. Measure not just note completion time, but error types, editing burden, omitted context, copied-forward inaccuracies, clinician-patient interaction, coding effects, and whether performance varies by accent, language, specialty, or environment.
For patient messages, constrain the role and sources. A system might draft a response using the patient’s record and approved education materials, but the responsible clinician should review clinical statements. High-risk topics—new symptoms, medication changes, suicidal ideation, pregnancy complications, or urgent test results—need deterministic routing and human escalation. The tool should not improvise outside its approved purpose because a patient asks a plausible question.
Retrieval-augmented generation can ground answers in approved policies or clinical content, but retrieval does not guarantee truth. The system may select the wrong document, use an outdated version, combine incompatible sources, or cite text that does not support the claim. Establish a controlled knowledge base with ownership, effective dates, versioning, and expiration. Require links or citations to source passages when useful, and test whether they truly support the output.
Prompt templates and system instructions are production configuration. Version them, review them, test them, restrict modification, and include them in change control. Build evaluation sets from realistic tasks and known failure cases. Automated scoring can help at scale, but human reviewers are needed for clinical nuance, harmful omissions, tone, and context. Red-team misuse and edge cases before release and periodically afterward.
Do not ask generative AI to perform a high-impact task simply because the output is readable. Fluent language can conceal uncertainty. Use structured checks, source grounding, constrained output formats, business rules, and human review in combination. Where exactness matters—drug doses, eligibility criteria, calculations, identity, or regulatory language—pair generation with authoritative systems and deterministic validation.
Portfolio discipline
Fund products and operating capabilities, not endless pilots
Many AI programs stall in a “pilot archipelago”: promising experiments owned by separate departments, each with custom data work, uncertain integration, temporary funding, and no path to scale. An enterprise portfolio changes the unit of management from a model to a product. A product includes the workflow, data pipeline, model or service, interface, controls, support, training, measurement, and accountable owner.
Calculate total cost of ownership across licensing, consumption fees, integration, data preparation, infrastructure, security, validation, workflow redesign, training, monitoring, support, vendor oversight, and retirement. Include the human review that safe use requires. A tool that saves two minutes but creates three minutes of correction is not productive. A tool that shifts work from physicians to already overloaded nurses may improve one department’s metric while harming the system.
Value should be causal enough for an investment decision. Establish a baseline and comparison approach before launch. Use phased rollouts, stepped-wedge designs, matched comparison groups, interrupted time series, or other practical methods when randomized evaluation is not feasible. Separate adoption from benefit: high usage can reflect a mandate, and low usage can reflect poor workflow fit rather than weak technology.
Create stage gates with explicit evidence requirements. Discovery validates the problem and alternatives. Feasibility tests data and technical integration. Validation examines performance and human interaction. Limited deployment tests operations and outcomes. Scale requires evidence, capacity, support, and a monitoring plan. Renewal requires continued value. Retirement should be normal when a product no longer performs, the workflow changes, a safer alternative emerges, or costs exceed benefit.
| Gate | Question leadership must answer | Minimum artifact |
|---|---|---|
| Discover | Is the problem important, measurable, and owned? | Baseline, workflow map, alternatives, equity implications |
| Validate | Does this version work safely in our context? | Local test plan, subgroup results, human-factors findings |
| Deploy | Can teams use it reliably with controls? | Training, support, downtime, escalation, monitoring dashboard |
| Scale | Did outcomes improve enough to justify expansion? | Outcome and balancing measures, cost and capacity analysis |
| Renew | Is it still safe, useful, and economically sound? | Performance trend, change history, incidents, realized value |
90-day activation plan
Move from scattered activity to controlled momentum
Days 1–30: establish visibility and authority
Name an executive sponsor and a small cross-functional governance core. Publish an interim definition of AI broad enough to capture predictive models, generative systems, embedded vendor features, robotic process automation with learned components, and patient-facing tools. Issue a simple intake form and require departments to register current and planned uses. Review software contracts and road maps for AI features that may already be enabled.
Inventory use cases and assign preliminary risk tiers. Identify unapproved tools handling sensitive data and provide staff with a safe enterprise alternative where possible. Define an urgent escalation route for suspected patient harm, privacy exposure, security events, discriminatory outcomes, or material model failure. Choose one common framework—such as the NIST AI RMF—to align vocabulary across clinical, technology, compliance, and risk teams.
Days 31–60: standardize evidence and controls
Create approval pathways for low-, medium-, and high-risk uses. Build templates for the use-case charter, vendor evidence request, data assessment, local validation plan, human-factors review, security and privacy review, patient communication, monitoring plan, and retirement plan. Map existing committees and controls to avoid duplication. For example, medical device review, clinical decision support, information security, privacy, research, and quality teams may already perform much of the needed work.
Select two or three priority products with committed owners and measurable baselines. Prefer a balanced portfolio: one lower-risk administrative opportunity that can demonstrate operating discipline, and one mission-relevant clinical or patient-facing opportunity with appropriate evidence and safeguards. Run tabletop exercises for failure, downtime, vendor change, and incident response.
Days 61–90: validate, deploy narrowly, and learn
Conduct local validation and silent-mode testing. Complete workflow simulations with representative users. Configure dashboards before users see the output. Deploy to a bounded environment with at-the-elbow support, rapid feedback, and clear stop criteria. Hold short, frequent reviews during the initial period, then adjust cadence based on risk and stability.
Report to the executive team in portfolio terms: number of registered systems, risk distribution, stage, accountable owner, evidence status, incidents, realized value, and decisions needed. Avoid a showcase composed only of model demonstrations. Leaders should see the operating system around the technology, including projects that were paused or rejected and why.
Questions for every vendor
- What exact version and intended use are we buying?
- What populations and settings were represented in development and external validation?
- What failures and subgroup limitations are known?
- How are model, prompt, or data changes communicated?
- What telemetry, audit logs, and performance data can we access?
- How are our data and prompts used, retained, and deleted?
- What support is provided for investigation, rollback, and regulatory obligations?
Questions for every owner
- What decision or task changes because of this tool?
- Who is accountable for the resulting action?
- What will users see, verify, override, and escalate?
- What is the safe fallback when the system fails?
- Which outcome and balancing measures determine success?
- Which groups could receive less benefit or more burden?
- What evidence would make us pause, redesign, or retire it?
Executive scorecard
Monitor the health of the AI portfolio
A board or executive committee does not need every technical metric. It needs assurance that the organization understands its exposure and is converting technology into mission-aligned results. A quarterly scorecard can show inventory completeness, risk mix, approvals, validation status, monitoring coverage, unresolved incidents, overdue vendor reviews, workforce feedback, patient concerns, realized outcomes, and total cost.
Pair lagging indicators—harm, denials, readmissions, complaints, and financial return—with leading indicators such as data-quality alerts, override patterns, subgroup drift, user training completion, queue growth, uptime, vendor changes, and time to resolve flagged outputs. Set thresholds that trigger review. A dashboard without a decision protocol only describes risk after it accumulates.
Review the portfolio as a learning system. Which projects produced value quickly, and what conditions made that possible? Which stalled on data, integration, adoption, or contracting? Which controls detected a problem early? What new reusable capabilities—identity, terminology, evaluation sets, monitoring, or staff expertise—can reduce the cost of the next deployment? Mature organizations get better at selecting and operating AI, not merely at buying it.
Transparency strengthens trust. Share appropriate information with clinicians, staff, patients, and community partners about how systems are selected, evaluated, monitored, and challenged. Publish plain-language principles and a pathway for questions. When an incident occurs, respond with the same seriousness used for other quality, privacy, or security events. Responsible disclosure and correction demonstrate that governance is real.
Evidence base
Sources and further reading
These primary resources support the governance, transparency, lifecycle, and risk-management practices discussed in this article.
- National Institute of Standards and Technology: AI Risk Management Framework
- NIST: Generative Artificial Intelligence Profile
- ASTP/ONC: Decision Support Interventions certification criterion
- U.S. Food and Drug Administration: Artificial Intelligence-Enabled Medical Devices
- FDA: Good Machine Learning Practice for Medical Device Development
